Eli Lilly is a publicly traded, Indianapolis-headquartered pharmaceutical firm listed on the NYSE — a genuinely American company with roots stretching back to 1875.
Yes, Lilly Is American
Eli Lilly is an American company, full stop. It's headquartered in Indianapolis, Indiana, trades on a major US stock exchange, and is included in the americancompanies.com directory of US-based companies. Beyond the paperwork, it's one of the country's oldest continuously operating pharmaceutical makers.
Roots in Indianapolis
The company's headquarters sit in Indianapolis, a fact that anchors its identity as a Midwestern institution as much as a global drug firm. That address isn't a satellite office or a regional hub — it's where the company has been based since its founding.
A Long American History
Eli Lilly was founded in 1875, which makes it a genuine relic of 19th-century American industry that has managed to stay relevant into the 21st. Few companies survive a century and a half; fewer still remain leaders in their field the whole way through.
From Storefront to Global Firm
What began generations ago has grown into a company with approximately 50,000 employees. That workforce reflects the scale required to research, manufacture, and distribute medicines used by patients around the world.
A Home on the New York Stock Exchange
Lilly is publicly traded under the ticker LLY on the NYSE, one of the most prominent US stock exchanges. Its IPO dates back to July 1970, meaning the company has been accountable to public shareholders for more than five decades. That long public listing is itself a marker of American corporate history — a company that went public well before most of today's household-name firms even existed.
Why the Listing Matters
A US stock exchange listing doesn't just signal financial transparency; it ties the company's fortunes to American capital markets and reporting standards. For a company this size, that public accountability has been a constant for generations.
What Lilly Actually Makes
Eli Lilly is a drug firm with a focus on neuroscience, cardiometabolic disease, cancer, and immunology. Its portfolio spans some of the most talked-about medicines in modern pharmaceuticals.
Cardiometabolic and Cancer Drugs
Key products include Verzenio and Jaypirca for cancer treatment, and Mounjaro, Zepbound, Foundayo, Jardiance, Trulicity, Humalog, and Humulin for cardiometabolic conditions. On the immunology side, the company markets Taltz and Olumiant. Together, these drugs touch millions of patients managing chronic and serious conditions.
The Scale of the Business Today
The numbers underline just how large Lilly has become. For fiscal year 2025, the company reported revenue of $65.2 billion and net income of $20.6 billion. Its total assets stand at $112.5 billion, and its market capitalization has reached $1.0 trillion — figures that place it among the largest pharmaceutical companies in the world.
Why the Answer Matters
When people ask whether a company is "American," they're usually asking about headquarters, stock listing, and origin story. On every one of those measures, Eli Lilly checks the box: an Indianapolis headquarters, a New York Stock Exchange listing since 1970, and a founding date of 1875. It's a company built and grown on American soil, now operating at a global scale in an industry that touches nearly every household.
